Chipotle Mexican Grill, Inc. vs Sana Biotechnology Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $35.82 (market cap $46.73B), while Sana Biotechnology Inc trades at $3.54 (market cap $994.89M). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 47× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| CMG | SANA | |
|---|---|---|
Market Cap | $46.73B | $994.89M |
Sector | Consumer Cyclical | Health |
52-Week High | $53.95 | $5.92 |
52-Week Low | $28.17 | $2.68 |
Enterprise Value | $51.11B | $969.08M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Trailing returns across standard periods
Latest headlines on both assets
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →